Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Febrile Neutropenia Industry By 2029?

In recent years, the market size for febrile neutropenia has seen significant growth. We forecast further expansion from $10.6 billion in 2024 to $11.28 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.4%. This growth in the historic period can be linked to several factors. These include an increase in cancer cases, wider acceptance of chemotherapy, the expansion of personalized medicine, reduction in healthcare costs, and an increased prevalence of neutropenia.

In the forthcoming years, the febrile neutropenia market size is projected to demonstrate solid growth, escalating to $14.35 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. The increase in the forecast period is owing to factors such as the widening use of immunosuppressive medications, expanded R&D, favorable insurance reimbursement strategies, augmented investments, and a surge in instances of leukemia. The forecast period will also see key trends including advanced molecular diagnostics, the introduction of antimicrobial stewardship & de-escalation therapy, the use of immunotherapy & targeted treatments, risk stratification models, and progress in fungal biomarkers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

Which Growth Drivers Are Shaping The Febrile Neutropenia Market Outlook?

The surge in cancer occurrences is predicted to boost the progress of the febrile neutropenia market. Cancer is a set of complex diseases marked by unchecked growth of irregular cells capable of invading neighboring tissues and propagating to different body parts. The escalation in cancer cases is due to reasons such as escalating age of the population, exposure to environmental & occupational hazards, genetic susceptibilities, and hormonal & reproductive influencers. Febrile neutropenia assists those with cancer by underlining the increased susceptibility to infections during chemotherapy, stimulating early intervention and personalized treatments, and thereby preventing potentially fatal complications. This in turn enhances patient results and facilitates the punctual continuation of cancer treatment. For example, the American Cancer Society, a non-profit organization based in the U.S. that raises awareness about cancer, estimated in January 2022 that around 1.9 million new cancer cases and 609,360 cancer-linked deaths in the U.S. are anticipated, leading to about 1,670 deaths daily. As such, the growing prevalence of cancer instigates the expansion of the febrile neutropenia market.

How Is The Global Febrile Neutropenia Market Broken Down By Segment?

The febrile neutropeniamarket covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy; Targeted Antibiotic Therapy; Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia; Transplant-Related Neutropenia; Genetic Disorders

3) By Etiology: Gram-Negative Bacteria; Gram-Positive Bacteria; Fungal Infections; Viral Infections

4) By Diagnostic Methods: Blood Cultures; Imaging Tests; Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams; Glycopeptides; Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy; Antiviral Therapy; Gram-Positive Bacterial Therapy; Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs); Intravenous Fluids; Antipyretics And Pain Management

Which Trends Are Likely To Redefine Growth Paths In The Febrile Neutropenia Market?

Major companies in the febrile neutropenia market are developing biosimilar drugs to improve treatment accessibility. Biosimilars are biological products closely mirroring approved reference drugs in terms of structure, function, and efficacy, offering more affordable alternatives while adhering to stringent regulatory standards. For instance, in September 2022, Germany-based pharmaceutical firm Fresenius Kabi obtained FDA approval for its biosimilar Stimufend (pegfilgrastim-fpgk). The drug is intended for patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy, which can lead to febrile neutropenia, a condition marked by low white blood cell count and fever. The company plans to release Stimufend in a prefilled syringe format in early 2023 and is also working on an on-body injector for future use.

Who Are The Primary Market Leaders In The Febrile Neutropenia Market?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Febrile Neutropenia Market?

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Browse Through More Reports Similar to the Global Febrile Neutropenia Market 2025, By The Business Research Company

Neutropenia Biologic Drug Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Chemotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model